Poisoning and Toxic Effects of Drugs with MCC DRG Reimbursement

DRG 917 encompasses inpatient admissions for poisoning and toxic effects of drugs when a Major Complication or Comorbidity is present, reflecting higher clinical complexity. This matters for inpatient reimbursement because the Major Complication or Comorbidity designation drives greater resource intensity and influences payment under Medicare.

DRG 917 Overview

DRG 917 covers hospital admissions for poisoning and toxic effects of drugs complicated by a Major Complication or Comorbidity. Typical cases include severe adverse drug reactions, intentional or unintentional overdoses, and toxic exposures requiring intensive monitoring or interventions. This Diagnosis-Related Group is important for Medicare payment because the presence of a Major Complication or Comorbidity substantially increases resource use and affects reimbursement classification. Accurate documentation of the toxic agent and the severity-related complications is central to correct inpatient payment assignment.

Acute resuscitation and antidote efficacy trials: randomized or pragmatic studies that evaluate time-sensitive emergency interventions, administration protocols, or newly developed antidotes in hospitalized patients presenting with severe drug poisoning and toxic effects with major complications (eg, respiratory failure, hemodynamic instability, or coma). These studies focus on the emergency and ICU phase of care, enrolling adults and sometimes pediatrics who require advanced airway management, vasopressors, or multi-organ support, and compare outcomes such as mortality, organ failure progression, and duration of intensive care. Results are directly relevant to clinicians and payers because they inform protocols that can shorten ICU stays, reduce complication rates, and allocate high-cost rescue therapies more effectively.
Comparative effectiveness and dosing strategy studies in complex polypharmacy or chronic-exposure populations: observational cohort studies or randomized comparative trials that examine different management strategies (eg, decontamination methods, stepwise detoxification protocols, or dosing regimens for reversal agents) among hospitalized patients with poisoning from prescription medications, illicit substances, or occupational exposures, often in patients with comorbidities like hepatic or renal impairment. These trials target subgroups at high risk for major complications to determine which approaches reduce progression to MCC status, readmission risk, and resource utilization. For providers and payers, this research helps identify cost-effective care pathways and patient selection criteria that can prevent escalation to more expensive critical-care resources.
Post-discharge outcomes, rehabilitation, and health-services research: prospective cohort studies and health-systems trials that follow survivors of poisoning with major complications after hospital discharge to evaluate functional recovery, neurocognitive outcomes, adherence to follow-up substance-use or psychiatric treatment, and rates of readmission or long-term healthcare utilization. These research efforts often include interventions such as structured discharge planning, linkage to outpatient addiction or mental health services, and case-management models, and enroll patients who required ICU care or had prolonged hospitalizations. Findings guide payers and health systems on investments in transitional care and community-based services that may reduce readmissions, improve long-term outcomes, and lower total cost of care for this high-risk DRG.

Acute resuscitation and antidote efficacy trials: randomized or pragmatic studies that evaluate time-sensitive emergency interventions, administration protocols, or newly developed antidotes in hospitalized patients presenting with severe drug poisoning and toxic effects with major complications (eg, respiratory failure, hemodynamic instability, or coma). These studies focus on the emergency and ICU phase of care, enrolling adults and sometimes pediatrics who require advanced airway management, vasopressors, or multi-organ support, and compare outcomes such as mortality, organ failure progression, and duration of intensive care. Results are directly relevant to clinicians and payers because they inform protocols that can shorten ICU stays, reduce complication rates, and allocate high-cost rescue therapies more effectively.
Comparative effectiveness and dosing strategy studies in complex polypharmacy or chronic-exposure populations: observational cohort studies or randomized comparative trials that examine different management strategies (eg, decontamination methods, stepwise detoxification protocols, or dosing regimens for reversal agents) among hospitalized patients with poisoning from prescription medications, illicit substances, or occupational exposures, often in patients with comorbidities like hepatic or renal impairment. These trials target subgroups at high risk for major complications to determine which approaches reduce progression to MCC status, readmission risk, and resource utilization. For providers and payers, this research helps identify cost-effective care pathways and patient selection criteria that can prevent escalation to more expensive critical-care resources.
Post-discharge outcomes, rehabilitation, and health-services research: prospective cohort studies and health-systems trials that follow survivors of poisoning with major complications after hospital discharge to evaluate functional recovery, neurocognitive outcomes, adherence to follow-up substance-use or psychiatric treatment, and rates of readmission or long-term healthcare utilization. These research efforts often include interventions such as structured discharge planning, linkage to outpatient addiction or mental health services, and case-management models, and enroll patients who required ICU care or had prolonged hospitalizations. Findings guide payers and health systems on investments in transitional care and community-based services that may reduce readmissions, improve long-term outcomes, and lower total cost of care for this high-risk DRG.

OpenPayer

Summary & Overview

Poisoning and Toxic Effects of Drugs with MCC: Inpatient Reimbursement Overview

DRG 917 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes